Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

INTRODUCTION: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Dumenil, Coraline, Massiani, Marie-Ange, Dumoulin, Jennifer, Giraud, Violaine, Labrune, Sylvie, Chinet, Thierry, Giroux Leprieur, Etienne
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2018
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912777/
https://ncbi.nlm.nih.gov/pubmed/29684049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0195945
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge